Pax6 Represses Androgen Receptor Activity
Author Information
Author(s): Julianne Elvenes, Ernst Ivan Simon Johnsen, Sylvia Sagen, Kaino Katrine Sjøttem, Eva Johansen, Terje Johansen
Primary Institution: Molecular Cancer Research Group, Institute of Medical Biology, University of Tromsø, Tromsø, Norway
Hypothesis
Pax6 inhibits androgen receptor (AR) activity by displacing coactivators.
Conclusion
Pax6 acts as a repressor of AR activity by inhibiting the recruitment of the coactivator SPBP.
Supporting Evidence
- Pax6 inhibits SPBP-mediated enhancement of AR activity.
- SPBP acts as a transcriptional coactivator of AR.
- Pax6 and SPBP compete for binding to the AR.
- Chromatin immunoprecipitation showed reduced SPBP association with the probasin promoter in the presence of Pax6.
Takeaway
Pax6 is like a stop sign for a car, telling the androgen receptor to slow down and not let too many helpers in, which is important for controlling prostate cancer.
Methodology
The study used luciferase reporter assays, chromatin immunoprecipitation, and coimmunoprecipitation to analyze the interactions between Pax6, SPBP, and AR.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website